CD274 and neoplasm: Immune checkpoint inhibitors, such aspembrolizumab, atezolizumab, and durvalumab, block the interaction between PD-1 onimmune cells and PD-L1 on cancer cells, thereby permitting the immune system toattack the tumor cells [31][32][33].